7UX Stock Overview
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Spago Nanomedical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.023 |
| 52 Week High | kr0.069 |
| 52 Week Low | kr0.017 |
| Beta | 2.1 |
| 1 Month Change | 1.79% |
| 3 Month Change | -10.24% |
| 1 Year Change | -63.23% |
| 3 Year Change | -96.75% |
| 5 Year Change | n/a |
| Change since IPO | -96.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7UX | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.6% | -5.1% | -2.0% |
| 1Y | -63.2% | -21.1% | -0.3% |
Return vs Industry: 7UX underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: 7UX underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| 7UX volatility | |
|---|---|
| 7UX Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7UX has not had significant price volatility in the past 3 months.
Volatility Over Time: 7UX's weekly volatility has decreased from 15% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 13 | Mats Hansen | spagonanomedical.se |
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer; and Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.
Spago Nanomedical AB (publ) Fundamentals Summary
| 7UX fundamental statistics | |
|---|---|
| Market cap | €5.89m |
| Earnings (TTM) | -€3.64m |
| Revenue (TTM) | €511.18k |
11.5x
P/S Ratio-1.6x
P/E RatioIs 7UX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7UX income statement (TTM) | |
|---|---|
| Revenue | kr5.93m |
| Cost of Revenue | kr24.49m |
| Gross Profit | -kr18.55m |
| Other Expenses | kr23.67m |
| Earnings | -kr42.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | -312.85% |
| Net Profit Margin | -711.90% |
| Debt/Equity Ratio | 0% |
How did 7UX perform over the long term?
See historical performance and comparison